Erratum to "Trypanosoma cruzi infection from the view of CD8+ T cell immunity - An infection model for developing T cell vaccine" [Parasitology International 57 (2008) 38-48] (DOI:10.1016/j.parint.2007.07.005);Trypanosoma cruzi infection from the view of CD8+ T cell immunity - An infection model for developing T cell vaccine

Parasitology International

Volumn 57, Issue 1, 2008, Pages 38-48

  Miyahira, Yasushi ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

CD8+ T cells; T cell vaccine; Trypanosoma cruzi

Indexed keywords

CD86 ANTIGEN; DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; PARASITE ANTIGEN;

ARTICLE; CD8+ T LYMPHOCYTE; CELL PROTECTION; CELLULAR IMMUNITY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSPOT ASSAY; GENETIC CODE; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PROTOZOAL INFECTION; SIGNAL TRANSDUCTION; TRYPANOSOMA CRUZI; VACCINATION;

BACTERIA (MICROORGANISMS); TRIATOMA; TRYPANOSOMA CRUZI;

EID: 36148956192     PISSN: 13835769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parint.2008.02.001     Document Type: Erratum

References (88)

1. Chagas C. Nova tripanozomiaze humana: estudos sobre a morfolojia e o ciclo evolutivo do Schizotrypanum cruzi n. gen., n. sp., agente etiolojico de nova entidade morbida do homem. Mem Inst Oswaldo Cruz 1 (1909) 159-218
2. Schofield C.J., Jannin J., and Salvatella R. The future of Chagas disease control. Trends Parasitol 22 (2006) 583-588
3. Moncayo A., and Ortiz Yanine M.I. An update on Chagas disease (human American trypanosomiasis). Ann Trop Med Parasitol 100 (2006) 663-677
4. Parrino J., and Graham B.S. Smallpox vaccines: past, present, and future. J Allergy Clin Immunol 118 (2006) 1320-1326
5. Robinson H.L., and Amara R.R. T cell vaccines for microbial infections. Nat Med 11 (2005) S25-S32
6. + T cells in vivo: the key to rational vaccine design. Annu Rev Immunol 23 (2005) 651-682
7. Burton D.R., Desrosiers R.C., Doms R.W., Koff W.C., Kwong P.D., Moore J.P., et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 5 (2004) 233-236
8. + memory T cells. Immunol Rev 211 (2006) 146-153
9. + T cell responses. Immunity 25 (2006) 533-543
10. Letvin N.L. Progress and obstacles in the development of an AIDS vaccine. Nat Rev Immunol 6 (2006) 930-939
11. Tsuji M., and Zavala F. T cells as mediators of protective immunity against liver stages of Plasmodium. Trends Parasitol 19 (2003) 88-93
12. Zinkernagel R.M., and Doherty P.C. The discovery of MHC restriction. Immunol Today 18 (1997) 14-17
13. McMichael A.J. HIV vaccines. Annu Rev Immunol 24 (2006) 227-255
14. Pamer E.G. Immune responses to Listeria monocytogenes. Nat Rev Immunol 4 (2004) 812-823
15. + T cells during malaria infection. Parasite Immunol 28 (2006) 15-24
16. + T-cell-mediated protective immunity against malaria. Proc Natl Acad Sci U S A 90 (1993) 5214-5218
17. + responses in mice. Proc Natl Acad Sci U S A 95 (1998) 3954-3959
18. + T-cell responses against malaria liver stages. Nat Med 8 (2002) 166-170
19. DosReis G.A. Cell-mediated immunity in experimental Trypanosoma cruzi infection. Parasitol Today 13 (1997) 335-342
20. + T cells increases susceptibility and reverses vaccine-induced immunity in mice infected with Trypanosoma cruzi. J Immunol 144 (1990) 717-724
21. 2-microglobulin-deficient mice to Trypanosoma cruzi infection. Nature 356 (1992) 338-340
22. Tarleton R.L., Grusby M.J., Postan M., and Glimcher L.H. Trypanosoma cruzi infection in MHC-deficient mice: further evidence for the role of both class I- and class II-restricted T cells in immune resistance and disease. Int Immunol 8 (1996) 13-22
23. + T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat Immunol 2 (2001) 415-422
24. van Stipdonk M.J., Lemmens E.E., and Schoenberger S.P. Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nat Immunol 2 (2001) 423-429
25. + T cells after infection. Nat Immunol 3 (2002) 619-626
26. + T-cell memory determined by clonal burst size. Nature 369 (1994) 652-654
27. + effector and memory T cell generation. Nat Immunol 4 (2003) 835-842
28. Kalia V., Sarkar S., Gourley T.S., Rouse B.T., and Ahmed R. Differentiation of memory B and T cells. Curr Opin Immunol 18 (2006) 255-264
29. Huster K.M., Stemberger C., and Busch D.H. Protective immunity towards intracellular pathogens. Curr Opin Immunol 18 (2006) 458-464
30. Grabstein K., and Chen Y.U. In: Mishell B.B., Shiigi S.M., Henry C., and Mishell R.I. (Eds). Selected Methods in Cellular Immunology (1980), Freeman, New York 124
31. + T cells using an ELISPOT assay. J Immunol Methods 181 (1995) 45-54
32. Murali-Krishna K., Altman J.D., Suresh M., Sourdive D.J., Zajac A.J., Miller J.D., et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 8 (1998) 177-187
33. Ogg G.S., and McMichael A.J. HLA-peptide tetrameric complexes. Curr Opin Immunol 10 (1998) 393-396
34. Dunachie S.J., and Hill A.V. Prime-boost strategies for malaria vaccine development. J Exp Biol 206 (2003) 3771-3779
35. Woodland D.L. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol 25 (2004) 98-104
36. Bejon P., Mwacharo J., Kai O., Mwangi T., Milligan P., Todryk S., et al. A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS Clin Trials 1 (2006) e29
37. Wizel B., Garg N., and Tarleton R.L. Vaccination with trypomastigote surface antigen 1-encoding plasmid DNA confers protection against lethal Trypanosoma cruzi infection. Infect Immun 66 (1998) 5073-5081
38. Costa F., Franchin G., Pereira-Chioccola V.L., Ribeirao M., Schenkman S., and Rodrigues M.M. Immunization with a plasmid DNA containing the gene of trans-sialidase reduces Trypanosoma cruzi infection in mice. Vaccine 16 (1998) 768-774
39. + T-cell epitopes are important for efficient protective immunity induced by DNA vaccination with a Trypanosoma cruzi gene. Infect Immun 69 (2001) 5477-5486
40. Katae M., Miyahira Y., Takeda K., Matsuda H., Yagita H., Okumura K., et al. Coadministration of an interleukin-12 gene and a Trypanosoma cruzi gene improves vaccine efficacy. Infect Immun 70 (2002) 4833-4840
41. Garg N., and Tarleton R.L. Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection. Infect Immun 70 (2002) 5547-5555
42. + T cell-mediated protective immunity against Trypanosoma cruzi. Int Immunol 11 (1999) 133-141
43. + T cell clones correlates with their levels of expression of adhesion molecules. J Exp Med 175 (1992) 895-905
44. + TC1 responses. J Immunol 159 (1997) 6120-6130
45. + CTL. J Immunol 160 (1998) 1817-1823
46. Rodrigues M.M., Ribeirao M., Pereira-Chioccola V., Renia L., and Costa F. Predominance of CD4 Th1 and CD8 Tc1 cells revealed by characterization of the cellular immune response generated by immunization with a DNA vaccine containing a Trypanosoma cruzi gene. Infect Immun 67 (1999) 3855-3863
47. Fralish B.H., and Tarleton R.L. Genetic immunization with LYT1 or a pool of trans-sialidase genes protects mice from lethal Trypanosoma cruzi infection. Vaccine 20,21 (2003) 3070-3080
48. +-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2. Infect Immun 73 (2005) 6017-6025
49. + T-Cell responses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes. PLoS Pathog 2 (2006) e77
50. +-T-cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection. Infect Immun 73 (2005) 7356-7365
51. Jechlinger W. Optimization and delivery of plasmid DNA for vaccination. Expert Rev Vaccines 5 (2006) 803-825
52. Donnelly J.J., Wahren B., and Liu M.A. DNA vaccines: progress and challenges. J Immunol 175 (2005) 633-639
53. Berzofsky J.A., Ahlers J.D., and Belyakov I.M. Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol 1 (2001) 209-219
54. + T cell response by DNA and viral vector vaccination. J Immunol 171 (2003) 6344-6348
55. Gurunathan S., Prussin C., Sacks D.L., and Seder R.A. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat Med 4 (1998) 1409-1415
56. Car B.D., Eng V.M., Lipman J.M., and Anderson T.D. The toxicology of interleukin-12: a review. Toxicol Pathol 27 (1999) 58-63
57. Theill L.E., Boyle W.J., and Penninger J.M. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 20 (2002) 795-823
58. Collins M., Ling V., and Carreno B.M. The B7 family of immune-regulatory ligands. Genome Biol 6 (2005) 223
59. Aggarwal B.B. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 3 (2003) 745-756
60. Miyahira Y., Katae M., Kobayashi S., Takeuchi T., Fukuchi Y., Abe R., et al. Critical contribution of CD28-CD80/CD86 costimulatory pathway to protection from Trypanosoma cruzi infection. Infect Immun 71 (2003) 3131-3137
61. Compton H.L., and Farrell J.P. CD28 costimulation and parasite dose combine to influence the susceptibility of BALB/c mice to infection with Leishmania major. J Immunol 168 (2002) 1302-1308
62. Brown D.R., Green J.M., Moskowitz N.H., Davis M., Thompson C.B., and Reiner S.L. Limited role of CD28-mediated signals in T helper subset differentiation. J Exp Med 184 (1996) 803-810
63. Brown J.A., Greenwald R.J., Scott S., Schweitzer A.N., Satoskar A.R., Chung C., et al. T helper differentiation in resistant and susceptible B7-deficient mice infected with Leishmania major. Eur J Immunol 32 (2002) 1764-1772
64. Rummel T., Batchelder J., Flaherty P., LaFleur G., Nanavati P., Burns J.M., et al. CD28 costimulation is required for the expression of T-cell-dependent cell-mediated immunity against blood-stage Plasmodium chabaudi malaria parasites. Infect Immun 72 (2004) 5768-5774
65. Elias R.M., Sardinha L.R., Bastos K.R., Zago C.A., da Silva A.P., Alvarez J.M., et al. Role of CD28 in polyclonal and specific T and B cell responses required for protection against blood stage malaria. J Immunol 174 (2005) 790-799
66. Hunter C.A., Ellis-Neyer L., Gabriel K.E., Kennedy M.K., Grabstein K.H., Linsley P.S., et al. The role of the CD28/B7 interaction in the regulation of NK cell responses during infection with Toxoplasma gondii. J Immunol 158 (1997) 2285-2293
67. Villegas E.N., Elloso M.M., Reichmann G., Peach R., and Hunter C.A. Role of CD28 in the generation of effector and memory responses required for resistance to Toxoplasma gondii. J Immunol 163 (1999) 3344-3353
68. Honstettre A., Meghari S., Nunes J.A., Lepidi H., Raoult D., Olive D., et al. Role for the CD28 molecule in the control of Coxiella burnetii infection. Infect Immun 74 (2006) 1800-1808
69. + T lymphocytes during infection with Listeria monocytogenes. J Immunol 167 (2001) 5620-5627
70. Hogan L.H., Markofski W., Bock A., Barger B., Morrissey J.D., and Sandor M. Mycobacterium bovis BCG-induced granuloma formation depends on gamma interferon and CD40 ligand but does not require CD28. Infect Immun 69 (2001) 2596-2603
71. Mittrucker H.W., Kohler A., Mak T.W., and Kaufmann S.H. Critical role of CD28 in protective immunity against Salmonella typhimurium. J Immunol 163 (1999) 6769-6776
72. + T cell-mediated resistance to an acute viral disease in a natural host. J Immunol 177 (2006) 8027-8036
73. -/- mice show defects in cellular and humoral immunity but are able to control infection with murine gammaherpesvirus 68. J Virol 76 (2002) 3049-3053
74. Bertram E.M., Tafuri A., Shahinian A., Chan V.S., Hunziker L., Recher M., et al. Role of ICOS versus CD28 in antiviral immunity. Eur J Immunol 32 (2002) 3376-3385
75. Suresh M., Whitmire J.K., Harrington L.E., Larsen C.P., Pearson T.C., Altman J.D., et al. Role of CD28-B7 interactions in generation and maintenance of CD8 T cell memory. J Immunol 167 (2001) 5565-5573
76. + effector T cell responses. J Immunol 164 (2000) 3689-3697
77. Stephenson J.R. Genetically modified viruses: vaccines by design. Curr Pharm Biotechnol 2 (2001) 47-76
78. Gherardi M.M., Perez-Jimenez E., Najera J.L., and Esteban M. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule. J Immunol 172 (2004) 6209-6220
79. Shiver J.W., and Emini E.A. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 55 (2004) 355-372
80. + T cell-mediated protective immunity against malaria. J Immunol 158 (1997) 1268-1274
81. + T cells. Virology 280 (2001) 155-159
82. Miyahira Y., and Dvorak J.A. Kinetoplastidaes display naturally occurring ancillary DNA-containing structures. Mol Biochem Parasitol 65 (1994) 339-349
83. Marin-Neto J.A., Cunha-Neto E., Maciel B.C., and Simoes M.V. Pathogenesis of chronic Chagas heart disease. Circulation 115 (2007) 1109-1123
84. Yewdell J.W., and Bennink J.R. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol 17 (1999) 51-88
85. Postan M., Bailey J.J., Dvorak J.A., McDaniel J.P., and Pottala E.W. Studies of Trypanosoma cruzi clones in inbred mice. III. Histopathological and electrocardiographical responses to chronic infection. Am J Trop Med Hyg 37 (1987) 541-549
86. Cunha-Neto E., Bilate A.M., Hyland K.V., Fonseca S.G., Kalil J., and Engman D.M. Induction of cardiac autoimmunity in Chagas heart disease: a case for molecular mimicry. Autoimmunity 39 (2006) 41-54
87. Tarleton R.L. Parasite persistence in the aetiology of Chagas disease. Int J Parasitol 31 (2001) 550-554
88. Aufderheide A.C., Salo W., Madden M., Streitz J., Buikstra J., Guhl F., et al. A 9000-year record of Chagas' disease. Proc Natl Acad Sci U S A 101 (2004) 2034-2039